Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers - 17th World ADC San Diego

Your Flagship Event Driving ADC Innovation, Insights & Connections

Register by Friday, August 7 & Save up to $600

Day

Hour

Minute

Second

Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
Novartis to acquire Myricx Bio for up to $1.5B, adding cancer-fighting ADC payload platform
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Gilead’s Trodelvy nabs broad FDA approval in front-line TNBC, fueling TROP2 ADC market war
J&J makes $1B upfront bet on emerging DAC space by netting Firefly Bio

Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers

12:00 pm - Tuesday 13th October 2026

Outlining design and development of STRO-006, an integrin beta-6 targeted DAR8 Topo1 ADC
Evaluating STRO-006 in a PDX clinical trial to identify biomarkers correlating with response
Undergoing translational workstreams to enable successful clinical development

Speakers:

Alice Yam

Alice Yam

Vice President - Drug Discovery

Sutro Biopharma